Key result
Among 87 patients with FSHD, common symptoms included pain (71%) and difficulty sleeping (41%), along with systemic manifestations such as sensorineural hearing loss (44% of those tested).
Why the study?
The full spectrum of the clinical phenotype of facioscapulohumeral muscular dystrophy beyond skeletal muscle weakness remains poorly characterized.
Cohort (n=87)
No
FSHD has a broad clinical phenotype including significant pain, sleep difficulties, and cardiac abnormalities, highlighting the need for comprehensive systemic screening.
INTRODUCTION/AIMS: The full spectrum of the clinical phenotype of facioscapulohumeral muscular dystrophy (FSHD), beyond skeletal muscle weakness, remains poorly characterized. In this study, we describe systemic manifestations and symptom burden in a large series of FSHD patients. METHODS: We performed a retrospective chart review of FSHD patients seen at our institution between 2000 and 2017. We reviewed patients' responses to a comprehensive review of symptoms and the results of diagnostic testing for sensorineural hearing loss, cardiac disease, dysphagia, ocular abnormalities, and respiratory insufficiency. We assessed the association between disease manifestations and age of onset, genetic profile, and disease duration. RESULTS: We identified 87 patients with FSHD. The most common reported symptoms included pain (71%), difficulty sleeping (41%), headaches (27%), and altered mood (24%). When tested, 7 of 16 (44%) patients had sensorineural hearing loss, 20 of 60 (33%) had cardiac arrhythmias or conduction defects, 17 of 45 (38%) had echocardiogram abnormalities, 12 of 25 (48%) had reduced forced vital capacity, and 4 of 10 (40%) had oropharyngeal dysphagia. However, patients with these abnormalities represented 8%, 23%, 20%, 14%, and 5% of total number of patients, respectively, as uniform screening was lacking. Ocular pathology attributable to FSHD was not detected. DISCUSSION: FSHD demonstrates a broad clinical phenotype. Increased vigilance among neurologists to screen for systemic manifestations of the disease is warranted. More uniform screening and future population-based studies are needed to compare findings in FSHD patients with the general population.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2022) conducted a cohort in Facioscapulohumeral muscular dystrophy (FSHD) (n=87). Facioscapulohumeral muscular dystrophy (FSHD) was evaluated on Systemic manifestations and symptom burden. Among 87 patients with FSHD, common symptoms included pain (71%) and difficulty sleeping (41%), along with systemic manifestations such as sensorineural hearing loss (44% of those tested).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: